Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

SCALING UP FRIDGE-FREE VACCINES STABLE AT +40°C

Project description

A thermostable tetanus and diphtheria vaccine

Stablepharma’s mission is to transform vaccine distribution using StablevaX™ technology, which produces thermostable vaccines that do not require cold storage. This technology can be used for over 60 approved vaccines, improving global access while reducing costs and waste. Its lead product, SPVX02, is a thermostable tetanus and diphtheria vaccine designed to overcome distribution barriers and extend access in underserved regions. The EIC-funded SUFFVSA40C project will advance SPVX02 through a Phase 2b clinical trial in collaboration with EU-based partners. After the trial, the project will seek market authorisation in the EU and other regions, aiming to expand the company’s portfolio with additional thermostable vaccines and pharmaceuticals using its StablevaX™ technology platform.

Objective

At Stablepharma, our mission is to revolutionise vaccine distribution and storage by leveraging our proprietary
StablevaX™ technology platform which results in the production of vaccines that are thermostable and do not require temperature controlled storage or distribution. Our technology can be applied to over 60 existing and currently, approved vaccines and our business model enable us to reformulate and thermostabilise existing, vaccines in partnership with vaccine manufacturers. By eliminating the need for cold-chain distribution and storage, we aim to enhance global access, reduce vaccine wastage, lower costs, and cut carbon emissions, all while enabling strategic stockpiling of vaccines.

Our lead product is SPVX02 (a thermostable tetanus and diphtheria (Td) vaccine) and is currently positioned to enter the largest global human vaccine market by dose volume (tetanus and diphtheria-containing vaccines) aside from COVID-19 in recent years. SPVX02 addresses critical challenges in vaccine distribution and storage, especially in regions where cold-chain logistics create barriers to vaccine access. By stabilising vaccines at ambient temperatures, we extend the reach and impact of life-saving vaccines, to all populations worldwide.

With the support of EIC funding, we intend to rapidly progress SPVX02 through a pivotal Phase 2b Clinical Trial, whilst collaborating with a range of EU-based manufacturing, clinical, and regulatory partners, before working with commercial distribution partners to apply for Market Authorisation in the EU and other regions. Ultimately, we plan to expand our portfolio to include additional thermostable vaccines and pharmaceuticals using our proprietary StablevaX™ technology platform enabling us to achieve our vision of saving lives and reducing wastage globally.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC - HORIZON EIC Accelerator

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2024-ACCELERATOR-02

See all projects funded under this call

Coordinator

STABLEPHARMA LIMITED
Net EU contribution
€ 2 499 999,00
Address
1 QUEEN SQUARE
BA1 2HA Bath
United Kingdom
SME
Yes
Region
South West (England) Gloucestershire, Wiltshire and Bristol/Bath area Bath and North East Somerset, North Somerset and South Gloucestershire
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data